Figure 2.

A/B: Axial (A) and coronal (B) fused [⁸⁹Zr]Zr-Df-IAB22M2C PET/MRI of Patient 7 after 4 cycles of combined ICT using ipilimumab and nivolumab until 6 weeks before the scan indicated only faint tracer uptake in a hilar lymph node metastasis (A), intense tracer uptake was found in an axillary lymph node metastasis (B). C/D: Axial (C) and coronal (D) fused [¹⁸F]FDG PET/CT images of Patient 7 five weeks before [⁸⁹Zr]Zr-Df-IAB22M2C PET/MRI indicated an intense glucose uptake of both the axillary and the hilar lymph node metastasis; these were considered to be viable tumor tissue. E/F: Eight weeks after [⁸⁹Zr]Zr-Df-IAB22M2C PET/MRI, the follow-up [¹⁸F]FDG PET/CT of Patient 7 revealed a decrease in axillary lymph node metastasis during ICT (F), while hilar lymph node metastasis (E) increased in size and [¹⁸F]FDG uptake during ICT monotherapy with nivolumab.